Amylyx Pharmaceuticals Inc
NASDAQ:AMLX 4:00:00 PM EDT
| Market Cap (Intraday) | 134.21M |
| Current PE | 2.72 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $2.28 |
| 50-Day MA | $8.80 |
| 200-Day MA | $15.54 |
Amylyx Pharmaceuticals Inc Stock, NASDAQ:AMLX
43 Thorndike Street, Cambridge, Massachusetts 02141
United States of America
Phone: +1.617.682.0917
Number of Employees: 384
Description
Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.